Get the Stockscreener App
45.95
2.45%
1.10
After Hours:
45.88
-0.07
-0.15%
Livanova Plc stock is traded at $45.95, with a volume of 932.28K.
It is up +2.45% in the last 24 hours and up +30.69% over the past month.
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
See More
Previous Close:
$44.85
Open:
$45.22
24h Volume:
932.28K
Relative Volume:
1.15
Market Cap:
$2.36B
Revenue:
$1.28B
Net Income/Loss:
$-222.15M
P/E Ratio:
-11.23
EPS:
-4.09
Net Cash Flow:
$145.52M
1W Performance:
+6.24%
1M Performance:
+30.69%
6M Performance:
-7.56%
1Y Performance:
-12.97%
1-Day Range:
$45.22
$46.11
1-Week Range:
$42.79
$46.11
52-Week Range:
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
Name
Livanova Plc
Sector
Industry
Phone
4402033250662
Address
20 EASTBOURNE TERRACE, LONDON
Compare LIVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
45.95 | 2.36B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Feb-26-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-04-24 | Initiated | Goldman | Buy |
| Sep-17-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-20-24 | Reiterated | Needham | Buy |
| Feb-20-24 | Upgrade | Mizuho | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Feb-24-22 | Upgrade | UBS | Neutral → Buy |
| Dec-03-21 | Initiated | Goldman | Buy |
| Aug-20-21 | Reiterated | Needham | Buy |
| Jul-20-21 | Upgrade | Needham | Hold → Buy |
| Mar-03-21 | Downgrade | Berenberg | Buy → Hold |
| Jan-05-21 | Downgrade | Needham | Buy → Hold |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-26-20 | Reiterated | Needham | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-08-18 | Initiated | Stifel | Buy |
| May-31-18 | Reiterated | Needham | Buy |
| Feb-28-18 | Reiterated | Needham | Buy |
View All
Livanova Plc Stock (LIVN) Latest News
LivaNova completes epilepsy treatment study of VNS Therapy - Medical Device Network
VNS therapy shows sustained seizure reduction in study By Investing.com - Investing.com South Africa
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - BioSpace
LivaNova at Jefferies Conference: Strategic Growth and Challenges - Investing.com
LivaNova at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Artificial Heart Lung Machines Market Projected to Witness - openPR.com
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study - GuruFocus
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study | LIVN Stock News - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy | LIVN Stock News - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy By Investing.com - Investing.com UK
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy | LIVN Stock - GuruFocus
LivaNova plc (LIVN) completes CORE-VNS study - StreetInsider
VNS therapy shows sustained seizure reduction in study - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - The Joplin Globe
LivaNova (LIVN) Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - StreetInsider
LivaNova seeks Medicare coverage reconsideration for VNS Therapy By Investing.com - Investing.com South Africa
LivaNova wants CMS to reconsider neuromod for treating depression - MassDevice
Bioelectronic Medicine Market Research Report 2025 Featuring Key PlayersMedtronic, Abbott, Boston Scientific, Cochlear, LivaNova, Soterix Medical, Bioinduction, GiMer Medical, CEFALY, BioControl - GlobeNewswire
LivaNova Seeks Reconsideration of National Medicare Coverage for VNS Depression Treatment - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Me - GuruFocus
LivaNova (LIVN) Seeks Expanded Medicare Coverage for VNS Therapy | LIVN Stock News - GuruFocus
LivaNova seeks Medicare coverage reconsideration for VNS Therapy - Investing.com India
LivaNova (LIVN) Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - StreetInsider
LivaNova Announces 12-month Data from OSPREY Study - Medical Product Outsourcing
Vagus Nerve Stimulation (VNS) Market Poised for Breakthrough Growth: From $488.5M in 2022 to $836.1M by 2032 - openPR.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Analysts - Defense World
Electroceuticals Market Generated Opportunities, Future - openPR.com
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles By Investing.com - Investing.com India
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles - Investing.com Australia
LivaNova's SWOT analysis: medical device firm's stock faces growth hurdles - Investing.com
(LIVN) Technical Data - news.stocktradersdaily.com
LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Deutsche Bank AG - Defense World
LivaNova faces $360M liability after court ruling By Investing.com - Investing.com South Africa
LivaNova faces $360M liability after court ruling - Investing.com India
LivaNova (NASDAQ:LIVN) Raised to Outperform at Wolfe Research - Defense World
LivaNova Faces Legal Dispute Over Environmental Liabilities - TipRanks
Wolfe Research Upgrades LivaNova (LIVN) - Nasdaq
LivaNova (LIVN) Receives Upgrade to "Outperform" by Wolfe Research | LIVN Stock News - GuruFocus
Wolfe Research lifts Livanova stock rating, sets $60 target By Investing.com - Investing.com Nigeria
LivaNova (LIVN) Upgraded by Wolfe Research with a Positive Outlo - GuruFocus
LivaNova (LIVN) Upgraded by Wolfe Research with a Positive Outlook | LIVN Stock News - GuruFocus
LivaNova (LIVN) Receives Upgrade to "Outperform" by Wolfe Resear - GuruFocus
Bank of America Corp DE Sells 94,006 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
LivaNova PLC (NASDAQ:LIVN) Shares Bought by BNP Paribas Financial Markets - Defense World
Combined Companies Sorin and Cyberonics Will Be Renamed LivaNova - Medical Product Outsourcing
LivaNova to Present at the Jefferies Global Healthcare Conference - The Joplin Globe
LIVN Stock Rating Reiterated at 'Buy' by Needham Analyst | LIVN - GuruFocus
LivaNova PLC (NASDAQ:LIVN) Q1 2025 Earnings Call Transcript - Insider Monkey
How to Take Advantage of moves in (LIVN) - news.stocktradersdaily.com
Livanova Plc Stock (LIVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Livanova Plc Stock (LIVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Makatsaria Vladimir | Chief Executive Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
9,330 |
0 |
9,330 |
| KOZY WILLIAM A | Director |
Mar 30 '25 |
Option Exercise |
0.00 |
1,034 |
0 |
28,496 |
| Hutchinson Michael Damon | Chief Legal Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
2,930 |
0 |
6,686 |
| Shvartsburg Alex | Chief Financial Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
11,083 |
0 |
30,196 |
| Poletti Franco | President, Cardiopulmonary |
Mar 30 '25 |
Option Exercise |
0.00 |
1,257 |
0 |
8,475 |
| Hutchinson Michael Damon | Chief Legal Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
2,254 |
0 |
4,540 |
| Poletti Franco | President, Cardiopulmonary |
Dec 15 '24 |
Option Exercise |
0.00 |
967 |
0 |
7,634 |
| Barry James Christopher | Director |
Dec 15 '24 |
Option Exercise |
0.00 |
1,709 |
0 |
1,709 |
| Shvartsburg Alex | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
613 |
0 |
19,342 |
| Bianchi Francesco | Director |
Dec 11 '24 |
Sale |
50.99 |
1,250 |
63,738 |
7,522 |
0.56%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):